Related Experiment Video
Updated: May 5, 2026
Measuring Caenorhabditis elegans Sensitivity to the Acetylcholine Receptor Agonist Levamisole
Published on: June 7, 2022
FER-1/Dysferlin promotes cholinergic signaling at the neuromuscular junction in C. elegans and mice
Predrag Krajacic1, Emidio E Pistilli, Jessica E Tanis
1Department of Physiology, Richards Research Building A702, University of Pennsylvania , Philadelphia, PA 19104 , USA ; Pennsylvania Muscle Institute, 700A Clinical Research Building, University of Pennsylvania , Philadelphia, PA 19104 , USA.
Abstract:
Dysferlin is a member of the evolutionarily conserved ferlin gene family. Mutations in Dysferlin lead to Limb Girdle Muscular Dystrophy 2B (LGMD2B), an inherited, progressive and incurable muscle disorder. However, the molecular mechanisms underlying disease pathogenesis are not fully understood. We found that both loss-of-function mutations and muscle-specific overexpression of C. elegans fer-1, the founding member of the Dysferlin gene family, caused defects in muscle cholinergic signaling. To determine if Dysferlin-dependent regulation of cholinergic signaling is evolutionarily conserved, we examined the in vivo physiological properties of skeletal muscle synaptic signaling in a mouse model of Dysferlin-deficiency. In addition to a loss in muscle strength, Dysferlin -/- mice also exhibited a cholinergic deficit manifested by a progressive, frequency-dependent decrement in their compound muscle action potentials following repetitive nerve stimulation, which was observed in another Dysferlin mouse model but not in a Dysferlin-independent mouse model of muscular dystrophy. Oral administration of Pyridostigmine bromide, a clinically used acetylcholinesterase inhibitor (AchE.I) known to increase synaptic efficacy, reversed the action potential defect and restored in vivo muscle strength to Dysferlin -/- mice without altering muscle pathophysiology. Our data demonstrate a previously unappreciated role for Dysferlin in the regulation of cholinergic signaling and suggest that such regulation may play a significant pathophysiological role in LGMD2B disease.
Insights
Dysferlin protein is crucial for muscle function. Its deficiency causes neuromuscular disorders like Limb Girdle Muscular Dystrophy 2B (LGMD2B) by impairing cholinergic signaling, treatable with acetylcholinesterase inhibitors.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Dysferlin is a protein linked to Limb Girdle Muscular Dystrophy 2B (LGMD2B), a progressive muscle disorder.
- The precise molecular mechanisms of LGMD2B pathogenesis remain unclear.
- Dysferlin belongs to the evolutionarily conserved ferlin gene family.
Purpose of the Study:
- To investigate the role of Dysferlin in regulating muscle cholinergic signaling.
- To determine if Dysferlin's role in cholinergic signaling is evolutionarily conserved.
- To explore potential therapeutic strategies for Dysferlin-deficient muscular dystrophy.
Main Methods:
- Studied C. elegans fer-1 gene function in muscle signaling.
- Examined skeletal muscle synaptic signaling in Dysferlin-deficient (Dysferlin-/-) mice.
- Assessed compound muscle action potentials and muscle strength.
- Administered Pyridostigmine bromide (an acetylcholinesterase inhibitor) to Dysferlin-/- mice.
Main Results:
- Dysferlin deficiency and C. elegans fer-1 mutations/overexpression impaired muscle cholinergic signaling.
- Dysferlin-/- mice exhibited progressive muscle weakness and a frequency-dependent deficit in compound muscle action potentials.
- Pyridostigmine bromide treatment restored action potential function and muscle strength in Dysferlin-/- mice without affecting muscle pathology.
Conclusions:
- Dysferlin plays a significant, previously unrecognized role in regulating muscle cholinergic signaling.
- Dysferlin-dependent cholinergic signaling is critical for maintaining neuromuscular function.
- Targeting cholinergic signaling may offer a therapeutic approach for LGMD2B and related muscular dystrophies.
